Gastroenterologia Japonica

, Volume 26, Issue 3, pp 303–311 | Cite as

Serological and immunohistochemical studies on sialylated carbohydrate antigens in colorectal carcinoma

  • Tohru Nakagoe
  • Hiroyuki Kusano
  • Masaki Hirota
  • Kiyoyasu Fukushima
  • Kazuto Hiratani
  • Kouhei Hara
  • Masao Tomita
Alimentary Tract


Sialylated carbohydrate antigens, such as CA19-9 (sialyl Lea), CA-50 (sialyl Lc4), CSLEX1 (sialyl Lex) and SLX (sialyl Lex-i), were assayed in the same preoperative serum samples of 63 patients with colorectal cancer, and compared with CEA. In addtion immunohistochemical expressions of sialyl Lea, sialyl lex and sialyl Lex-i antigens were studied in 62 colorectal carcinomas and 42 normal mucosal sites remote from the malignant lesion using monoclonal antibodies CSLEA1, CSLEX1 and FH-6, respectively, in order to elucidate their tumor-specificity and clinical usefulness as a tumor-associated antigen. Serologically, the percent positive rates of CA19-9, CA-50, CSLEX1, SLX and CEA were 30.2%, 17.7%,23.8%, 16.1% and 44.4%, respectively. In dukes’ A and B, these sialylated carbohydrate antigens, especially CSLEX1 and SLX, showed low positive rates, but the percent positive rates of CSLEX1 and SLX correlated with operative radicality. The positive spectrum of CSLEX1 differed from that of CA19-9 in sera, and CEA had no correlation with these two antigens. The immunohistochemical expression rates of sialyl Lea, sialyl Lex and sialyl Lex-i were 88.1%, 17.0% and 9.5% in normal mucosa, but were 77.8%, 90.5% and 71.4% in carcinoma, respectively. These data suggested that the type 2 chain antigens CSLEX1 and SLX, which have high tumor-specificity compared with CA19-9, may be useful in preoperative diagnosis for extention of carcinoma and operative radicality, althogh early diagnosis using these sialylated carbohydrate antigens may be difficult, while the combined use of CA19-9, CSLEX1 and CEA should make it possible to detect a wide range of colorectal cancer patients.

Key words

colorectal cancer sialylated carbohydrate antigen sialyl lewisa sialyl lewisx sialyl lewisx-i 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Koehler G Milstein C: Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497CrossRefGoogle Scholar
  2. 2.
    Koprowski H, Steplewski Z, Mitchell K, et al: colorectal carcinoma antigens detected by hybridoma antibodies. Soma. Cell Genet 1979;5:957–972CrossRefGoogle Scholar
  3. 3.
    Magnani JL, Nilsson B, Brockhause M, et al: A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaosell. J Biol Chem 1982;257:14365–14369PubMedGoogle Scholar
  4. 4.
    Lindholm L, Holmgren J, Svennerholm P, et al: Monoclonal antibodies against gastrointestinal tumor-associated antigens isolated as monosialoganglioside. Int Arch Allergy Appl Immunol 1983;71:178–181PubMedGoogle Scholar
  5. 5.
    Fukushima K, Hirota M, Terasaki P, et al: Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res 1984;44:5279–5285PubMedGoogle Scholar
  6. 6.
    Fukushi Y, Nudelman E, Levery SB, et al: Novel fucolipids accumulating in human cancer. III. A hybridoma antibody (FH-6) defining a human cancer-associated fucogangliodise (VI3NeuAcV3III3Fuc2 nLc6). J Biol Chem 1984;259:10511–10517PubMedGoogle Scholar
  7. 7.
    Kannagi R, Fukushi Y, Tachikawa T, et al: Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res 1986;46:2619–2626PubMedGoogle Scholar
  8. 8.
    Galton J, Terasaki PI, Wakisaka A, et al: A monoclonal antibody reactive with colonic, gastric and pancreatic adenocarcinomas. 9th Int Convoc Immunol, Amherst, New York. 1984; 117–125Google Scholar
  9. 9.
    Kaszubowski PA, Terasaki PI, Chia DS, et al:A cytotoxic monoclonal antibody to colon adenocarcinoma. Cancer Res 1984;44:1194–1199PubMedGoogle Scholar
  10. 10.
    Hakomori S: Aberrant gylcosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res 1985;45:2405–2414PubMedGoogle Scholar
  11. 11.
    Magnani J, et al: Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as mucin. Cancer Res 1983;43: 5489–5492PubMedGoogle Scholar
  12. 12.
    Arends JW, Verstynen C, Bosman FT, et al: Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: An immunoperoxidase study. Hybridoma 1983;2:219–229PubMedCrossRefGoogle Scholar
  13. 13.
    Hakomori S, Nudelman E, Levery SB, et al: Novel fucolipids accumulating in human adenocarcinoma. I.Glycolipids with dior tri-fucosylated type 2 chain. J Biol chem 1984;259:4672–4680PubMedGoogle Scholar
  14. 14.
    Yang H-J, Hakomori S:A, Sphingolipid having a novel type of ceramide and “lacto-N-fucopentaose III”. J Biol Chem 1971;246:1192–1200PubMedGoogle Scholar
  15. 15.
    Fukushi Y, Kannagi R, Hakomori S, et al: Localization and distribution of difucoganglioside (VI3Neu AcV3III3 Fuc2 nLc6) in normal and tumor tissues defined by its monoclonal antibody FH-6. Cancer Res 1985;45:3711–3717PubMedGoogle Scholar
  16. 16.
    Solter D, Knowles BB: Monoclonal antibody defining a stagespecific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci USA 1978;75:5565–5569PubMedCrossRefGoogle Scholar
  17. 17.
    Fox N, Damjanov I, Martinez-Hernandez A, et al: Immunohistochemical localization of the early embryonic antigen (SSEA-1) in postimplantation mouse embryos and fetal and adult tissues. Dev. Biol 1981;83:391–398PubMedCrossRefGoogle Scholar
  18. 18.
    Blaszczyk M, Ross AH, Ernst CS, et al: Fetal glycolipid expressed on adenocarcinomas of the colon. Int J Cancer 1984;33: 313–318PubMedCrossRefGoogle Scholar
  19. 19.
    Bosmann HB, Hall TC: Enzyme activity in invasive tumors of human breast and clon. Proc Natl Acad Sci USA 1974;71:1883–1887CrossRefGoogle Scholar
  20. 20.
    Ganzinger U, Deutsch E: Serum sialyltransferase levels as a parameter in the diagnosis and follow-up of gastrointestinal tumors. Cancer Res 1980;40:1300–1304PubMedGoogle Scholar
  21. 21.
    Yoshikawa T, Nishida Tanigawa et al: Carbohydrate antigenic determinant (CA19-9) and other tumor markers in gastrointestinal malignancies. Digestion 1985;31:67–76PubMedGoogle Scholar
  22. 22.
    Ritts RE, Del Villano BC, Go VLW, et al: Initial climincal evaluation of an immunoradiometric assay for CA19-9 using the NCI serum bank. Int J Cancer 1984;33:339–345PubMedCrossRefGoogle Scholar
  23. 23.
    Herlyn M, Sears HF, Steplewski Z, et al: Monoclonal antibody detection of a circulation tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982;2:135–140PubMedCrossRefGoogle Scholar
  24. 24.
    Satake K, Kanazawa G, Kho I, et al: A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma. J Surg Oncol 1985;29:15–21PubMedCrossRefGoogle Scholar
  25. 25.
    Hirota M, Fukushima K, Terasaki PI, et al: Sialosylated Lewisx in the sera of cancer patients detected by a cell-binding inhibition assay. Cancer Res 1985;45:1901–1905PubMedGoogle Scholar
  26. 26.
    Iguro T: Application of monoclonal antibody to detect the red cell associated antigen Lewisx and sialylated Lewisx in the serum of cancer patient. J Jpn Surg Soc 1987:88:1407–1414 (in Japanese)Google Scholar
  27. 27.
    Chia D, Terasaki PI, Suyama N, et al: Use of monoclonal antibodies to sialylated Lewisx and sialylated Lewisa for serological tests of cancer. Cancer Res 1985;45:435–437PubMedGoogle Scholar
  28. 28.
    Imura H, Endo J, Ohkura H, et al: Initial basic and clinical evaluation of a solid-phase immunoradiometric assay for sialyl SSEA-1 antigen: 2. Evaluation of clinical significance. Jpn J Cancer Chemother 1987;14:1322–1331 (in Japanese)Google Scholar
  29. 29.
    Koprowski H, Brockhause M, Blaszczyk M, et al: Lewis bloodtype may affect the incidence of gastrointestinal cancer. Lancet 1982;1:1332–1333PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Gastroenterology 1991

Authors and Affiliations

  • Tohru Nakagoe
    • 1
  • Hiroyuki Kusano
    • 1
  • Masaki Hirota
    • 2
  • Kiyoyasu Fukushima
    • 2
  • Kazuto Hiratani
    • 2
  • Kouhei Hara
    • 2
  • Masao Tomita
    • 1
  1. 1.First Department of SurgeryNagasaki University School of MedicineNagasakiJapan
  2. 2.Second Department of Internal MedicineNagasaki University School of MedicineNagasakiJapan

Personalised recommendations